About PETcura — Precision Oncology for Pets in China

Translating proven human-medicine platforms to pets

PETcura Biotechnologies is a Chinese biotech company specializing in precision oncology for pets, headquartered in Beijing. Core services include canine personalized mRNA immunotherapy (IIT study), pet tumor organoid drug sensitivity testing, and canine tumor gene sequencing with targeted drug prediction. PETcura partners with hospitals across 9 cities in China, translating proven human-medicine precision oncology platforms to pets so that every treatment decision for a cancer patient is evidence-based.

PETcura — finding the next path for your dog's life. PETcura Biotechnologies (Beijing) Ltd. connects frontier biotechnology with companion-animal clinical needs, providing integrated precision oncology solutions for pet hospitals and pet owners in China.

Three service lines

Service	Position	Details
Canine personalized mRNA immunotherapy	Investigator-initiated study (IIT)	Tumor RNA sequencing + AI neoantigen analysis, custom mRNA-LNP per dog; enrolling at 12 partner hospitals in 9 cities
Tumor drug sensitivity testing	Available service	3D organoid platform, 48 chemo/targeted drugs tested on a tumor "stand-in", ~10-day report
Canine gene testing & targeted drug guidance	Coming soon (notification signup available)	154-gene pan-cancer panel, A-D evidence tiers, targeted drug guidance report

Organization & technical support

Sponsor: PETcura — overall coordination, clinical operations, quality control; funds core R&D and manufacturing costs
Technical advisor: Chuangmo Bio (创模生物) — scientific route assurance and translational experience in human mRNA tumor immunotherapy
Technical supply: a leading mRNA research institution — neoantigen AI prediction, mRNA sequence design, formulation synthesis, LNP encapsulation, quality release
Clinical execution: licensed veterinarians at partner hospitals in 9 cities (site PIs) — enrollment assessment, injections, follow-up

Research nature

The canine personalized mRNA immunotherapy is an investigator-initiated exploratory study (IIT) — not a commercially approved veterinary product. The study is at an exploratory stage: enrollment and efficacy are not guaranteed; mRNA immunotherapy does not alter the dog's genome and does not replace standard treatment. All participation requires licensed-veterinarian assessment and signed informed consent.

Contact

📱 WeChat: petcura
📞 Phone: +86 150 6193 1301
✉️ Email: petcura@imodels.tech
🌐 Handbook: handbook.petcura.cn
🏢 Address: Building 14, Floor 3, Life Valley Industrial Base, Nanshao Town, Changping District, Beijing

Learn more: mRNA immunotherapy IIT · Gene testing · Drug sensitivity testing